Welcome to our Investor Information Center
General Meetings of Shareholders

Milestone Medical Inc. will hold the Annual Meeting of Shareholders on Friday, September 1, 2023 at 9:00 am ET in Roseland, New Jersey, United States of America at the corporate office of the Company, located at 425 Eagle Rock Avenue, Suite 403. The record date for the notice of the meeting, the record date for voting, and the date of the determination of beneficial ownership shall be July 5, 2023.

Further information concerning the Meeting will be given by the Issuer by way of subsequent current reports and at the Company’s website.

Company Overview

Innovative.  Award-Winning.  Team-Driven.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc.

The Company, through Milestone Scientific, has since entered into an exclusive distribution agreement with Tri-anim Health Services, Inc., the largest provider of specialty sales and distribution solutions for healthcare in the U.S., to market the epidural system to healthcare facilities, the home healthcare market, the acute care market, long term acute care and US Government acute care facilities, other than non-hospital based pain management practices. The Company also has a distribution agreement with Beijing 3H, a medical equipment distribution company in China, for distribution of the products in the People's Republic of China, Macao, Hong Kong and other regions of Asia, where Beijing 3H has established distribution channels.

Milestone Medical Inc. was formed in 2011 as a result of a joint venture between Milestone Scientific Inc. and Beijing 3H (Heart-Help-Health) Scientific Technology Co., Ltd. for the development, commercialization, manufacturing and marketing of epidural and intra-articular injection instruments.

In forming the joint venture, Milestone Scientific contributed an exclusive worldwide royalty-free license for Milestone Medical to use its patents for epidural and intra-articular applications, and the other shareholders of Milestone Medical contributed $1.5 million to develop and commercialize these instruments and their disposables.

Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union.

The core technologies and patents underlying Milestone Medical's license were originally developed and used by Milestone Scientific in breakthrough dental applications; more than 50 million injections have been administered to date.